Phibro Animal Health Corporation Class A PAHC

Phibro Animal Health Corp is a world-wide diversified animal health and mineral nutrition company. It strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise and care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. It develop, manufacture and market products for food animals including poultry, beef and dairy cattle, swine, aquaculture and dogs. It has three segments Animal Health, Mineral Nutrition, and Performance Products. Majority of revenue comes from Animal Health segment. Animal health products are anti-bacterials, anticoccidials, nutritional specialty products, and vaccines, and vaccine adjuvants that help improve the animal's health.

Con 27 acciones de PAHC (USD 1.005,64) habrías recibido USD 12,96 en dividendos en los últimos 12 meses.

• Zacks Investment Research 1 oct

  Neogen Stock Rallies 83% YTD: What's Driving the Surge?

  Neogen (NEOG) shares have surged 83% year-to-date, outperforming the S&P 500, driven by strong Food Safety segment growth with core revenue increases of 5.8% in Q4 fiscal 2026. The company is expanding manufacturing capabilities following its 3M Food Safety acquisition, planning a 50% increase in R&D spending for fiscal 2027 focused on pathogen detection and sanitation platforms. However, fiscal 2027 EPS is projected to decline 3.1% before recovering with 17.2% growth in fiscal 2028.

  

• Zacks Investment Research 30 sept

  Should You Continue to Hold IART Stock in Your Portfolio?

  Integra LifeSciences (IART) reported 1.6% organic growth in Specialty Surgery revenues driven by neurosurgery strength and improved supply reliability. Adjusted EPS rose 24.4% with margin expansion, and the company is ramping up Braintree production for a SurgiMend relaunch. However, elevated leverage at 4.1X and foreign exchange headwinds pressured full-year revenue guidance and financial flexibility.

  

• Zacks Investment Research 29 sept

  Chewy's Vet Care Posts Triple-Digit Growth as Clinic Scale Builds

  Chewy's Vet Care portfolio achieved triple-digit revenue growth in Q2, demonstrating strong customer satisfaction, veterinarian retention, and compelling clinic economics. The company expects its Health segment, including Modern Animal, to deepen customer engagement and expand wallet share as it scales. However, Chewy carries a Zacks Rank #4 (Sell) rating and has underperformed its industry by 44.7% over the past six months.

  

• Zacks Investment Research 29 sept

  Is This the Right Time to Add Labcorp Stock to Your Portfolio?

  Labcorp Holdings is expanding its specialty testing business in oncology, women's health, autoimmune disease, and neurology through strategic acquisitions and partnerships. The company is leveraging AI and automation to improve margins, with operating margins expanding 70 basis points year-over-year. However, macroeconomic uncertainty, cost inflation, and changing reimbursement policies pose risks to testing volumes and profitability.

  

• Zacks Investment Research 18 sept

  PAHC vs. HAE: Which Stock Should Value Investors Buy Now?

  In a comparison of two Medical-Products sector stocks, Phibro Animal Health (PAHC) emerges as the better value opportunity compared to Haemonetics (HAE). PAHC holds a Zacks Rank #2 (Buy) with a Value grade of A, featuring a forward P/E of 10.06 and PEG ratio of 1.02. HAE has a Zacks Rank #3 (Hold) with a Value grade of C, showing a forward P/E of 20.36 and PEG ratio of 2.15, making PAHC more attractive to value investors.